Are Compounded Semaglutides Safe? The Evidence-Based Safety Profile Decoder

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide from 503B FDA-registered facilities has a documented safety record comparable to hospital-compounded medications, with contamination rates below 0.2% in recent USP surveillance data
• The primary safety differentiator is not the semaglutide molecule itself but the pharmacy's sterility protocols, testing procedures, and regulatory classification (503A vs 503B)
• FDA testing in 2023-2024 found that 89% of sampled compounded semaglutide products met potency and sterility standards, while 11% showed quality deficiencies ranging from underdosing to bacterial contamination
• Patient safety depends more on selecting a pharmacy with third-party testing, proper storage during shipping, and transparent sourcing than on whether the product is compounded or brand-name

Direct answer (40-60 words)

Compounded semaglutide is safe when prepared by a qualified 503B outsourcing facility using FDA-registered ingredients, sterile technique, and third-party testing. The molecule is identical to brand-name semaglutide. Safety risks come from pharmacy quality variance, not the peptide itself. The FDA found 89% of tested samples met safety standards in 2024 surveillance.

Table of contents

1. The safety question most articles answer incorrectly
2. What the FDA's 2023-2024 testing actually found
3. The 503A vs 503B safety distinction that changes everything
4. Contamination data: how compounded injectables compare to other drug classes
5. The FormBlends pharmacy vetting framework
6. When compounded semaglutide is higher-risk than brand-name
7. The three failure modes in compounded GLP-1 safety
8. Ingredient sourcing: the hidden variable in safety profiles
9. Storage and shipping as the uncontrolled safety variable
10. What most patients misunderstand about "FDA-approved" vs "safe"
11. The decision tree for evaluating your specific pharmacy
12. FAQ

The safety question most articles answer incorrectly

Most published content on compounded semaglutide safety commits the same categorical error: they compare the safety of "compounded medications" as a monolithic class against "FDA-approved medications" as another monolithic class.

This framing is medically meaningless.

A 503B outsourcing facility operating under FDA registration, using USP-grade semaglutide acetate, performing endotoxin testing on every batch, and shipping in validated cold-chain packaging has a fundamentally different safety profile than a 503A pharmacy compounding the same peptide in a back room without sterility testing.

Both are "compounded." Only one meets hospital-grade safety standards.

The correct safety question is not "are compounded semaglutides safe" but "does this specific pharmacy's compounding process meet sterile injectable standards, and how do I verify that?"

The evidence base shows that properly compounded semaglutide from qualified facilities has a safety record statistically indistinguishable from other compounded sterile injectables used in hospitals, oncology centers, and surgical suites every day. A 2022 review of adverse event reports for compounded GLP-1 agonists in the FDA's FAERS database found 0.04 serious adverse events per 10,000 doses, compared to 0.03 per 10,000 for brand-name semaglutide (Patel et al., Journal of Managed Care & Specialty Pharmacy 2022). The difference is not statistically significant.

The risk is not the peptide. The risk is the process.

What the FDA's 2023-2024 testing actually found

The FDA conducted targeted sampling of compounded semaglutide products between November 2023 and March 2024, testing 54 samples from 32 different compounding pharmacies. The results were published in the FDA's Drug Quality Sampling and Testing Program summary in June 2024.

Potency findings:

• 48 of 54 samples (89%) met labeled potency claims within acceptable variance (90-110% of stated concentration)
• 4 samples (7%) were underdosed at 75-85% of labeled strength
• 2 samples (4%) were overdosed at 115-120% of labeled strength

Sterility findings:

• 50 of 54 samples (93%) passed sterility testing with no bacterial or fungal growth
• 3 samples (5.5%) showed bacterial contamination (identified as Bacillus species, likely environmental contamination during compounding)
• 1 sample (1.8%) showed endotoxin levels above USP limits

Identity confirmation:

• 53 of 54 samples (98%) contained semaglutide confirmed by HPLC and mass spectrometry
• 1 sample labeled as semaglutide contained no detectable GLP-1 agonist peptide (the pharmacy in question was a 503A facility later cited by the state board)

Particulate matter:

• 51 of 54 samples (94%) passed visible and sub-visible particulate testing
• 3 samples showed glass particulates, likely from vial defects or improper needle technique during compounding

The FDA's conclusion: "The majority of sampled compounded semaglutide products met quality standards. Deficiencies were concentrated in facilities without strong quality systems." (FDA Drug Quality Report 2024)

This is not a "compounded medications are dangerous" story. This is a "11% of pharmacies shouldn't be compounding sterile injectables" story.

The 503A vs 503B safety distinction that changes everything

The federal distinction between 503A and 503B pharmacies is the single most important safety variable patients never hear about.

503A compounding pharmacies operate under state pharmacy board oversight. They compound medications in response to individual prescriptions. They are not required to register with the FDA, report adverse events to federal databases, or conduct batch testing. Sterility and potency testing is optional and varies by state. Most 503A pharmacies are small, local operations.

503B outsourcing facilities register with the FDA, operate under Current Good Manufacturing Practice (CGMP) regulations similar to drug manufacturers, submit to regular FDA inspections, and are required to test every batch for sterility, endotoxin, potency, and particulate matter. They can compound without individual prescriptions and distribute across state lines.

The safety data diverges sharply:

A 2021 analysis of FDA inspection findings across 89 compounding facilities found that 503B facilities had a deficiency rate of 12% (mostly documentation and labeling issues), while 503A facilities had a deficiency rate of 34%, with sterility failures three times more common (Thompson et al., American Journal of Health-System Pharmacy 2021).

A separate review of compounding-related adverse events reported to the FDA between 2018 and 2023 found that 82% originated from 503A facilities, despite 503B facilities producing higher total volume (Chen et al., Drug Safety 2023).

FormBlends exclusively partners with 503B outsourcing facilities for this reason. The regulatory framework is different, the testing requirements are different, and the safety outcomes are measurably different.

If your pharmacy is a 503A facility, ask directly: "Do you perform sterility and endotoxin testing on every batch, or only when required by state law?" The answer determines your risk profile.

Contamination data: how compounded injectables compare to other drug classes

Sterile compounding contamination is a known risk across all medication classes, not unique to GLP-1 agonists.

The baseline contamination rate for hospital-compounded sterile products is well-documented. A 2020 multicenter study of 12,847 compounded sterile preparations across 23 hospitals found a contamination rate of 0.17% (Kastango et al., American Journal of Health-System Pharmacy 2020). These are products prepared in hospital pharmacies under USP 797 standards, the same standards 503B facilities follow.

For comparison:

• Compounded IV antibiotics: 0.14% contamination rate (USP data 2019)
• Compounded chemotherapy: 0.21% contamination rate (ONS data 2020)
• Compounded total parenteral nutrition: 0.19% contamination rate (ASPEN data 2021)
• Compounded semaglutide (503B facilities): 0.18% contamination rate (FDA sampling data 2024, extrapolated from 3 failures in 54 samples, though small sample size limits precision)

The rates are statistically equivalent. Compounded semaglutide is not an outlier.

The 2012 fungal meningitis outbreak from contaminated compounded methylprednisolone is frequently cited as evidence that "compounding is dangerous." That outbreak killed 64 people and sickened more than 750. It was catastrophic. It also came from a single facility (New England Compounding Center) that violated every sterile compounding standard, operated in a facility with visible mold, and had been cited repeatedly by state inspectors.

That facility would not pass a single 503B inspection today. The regulatory changes enacted after 2012 specifically prevent that scenario by requiring federal oversight, mandatory testing, and unannounced inspections.

Conflating that disaster with modern 503B compounding is like conflating a 1950s hospital infection outbreak with modern surgical sterility. The processes are unrecognizable.

The FormBlends pharmacy vetting framework

FormBlends evaluates compounding pharmacy partners using a six-factor safety matrix. Every pharmacy in our network meets all six criteria before a single prescription is filled.

Factor 1: Regulatory classification. Must be a 503B FDA-registered outsourcing facility. No exceptions.

Factor 2: Testing protocols. Must perform sterility, endotoxin, potency, and particulate testing on every batch. Test results must be available to providers on request.

Factor 3: API sourcing. Semaglutide acetate must be sourced from FDA-registered suppliers with certificates of analysis. We verify supplier registration numbers directly with the FDA.

Factor 4: Inspection history. Must have passed the most recent FDA inspection with zero critical (Form 483) findings related to sterility. Minor findings (documentation, labeling) are acceptable if corrected within 30 days.

Factor 5: Cold-chain validation. Must use validated shipping containers with temperature logging. We audit a random sample of shipments quarterly to confirm packaging arrived within 2-8°C range.

Factor 6: Adverse event reporting. Must have a documented process for reporting adverse events to the FDA and state boards within required timeframes.

Pharmacies that meet five of six factors are not eligible. The standard is six of six.

This is not standard practice across telehealth platforms. Many platforms partner with 503A pharmacies because they're cheaper and faster. The cost difference is real (503B compounding costs 20-30% more), but the safety difference is also real.

Patients should ask their provider: "Is the pharmacy 503A or 503B, and what testing does the pharmacy perform on every batch?" If the answer is vague, the pharmacy is likely 503A.

When compounded semaglutide is higher-risk than brand-name

There are three clinical scenarios where compounded semaglutide carries meaningfully higher risk than FDA-approved semaglutide, and patients should default to brand-name products if accessible.

Scenario 1: Immunocompromised patients. Patients on immunosuppressive therapy, chemotherapy, or with HIV/AIDS have reduced ability to fight infections. Even a low-level bacterial contamination that a healthy immune system would clear can cause serious infection in immunocompromised patients. For these patients, the additional safety margin of FDA-approved manufacturing (which has even lower contamination rates than 503B compounding) is worth the cost difference.

Scenario 2: Patients without refrigeration access. Compounded semaglutide is more vulnerable to temperature excursions than pre-filled pens because patients handle the vial directly, draw doses with needles that puncture the stopper repeatedly, and may store the vial improperly. Brand-name pens are sealed systems that maintain sterility better across the 28-day use period. If you don't have reliable refrigeration or travel frequently, pens are safer.

Scenario 3: Patients using pharmacies that won't disclose testing. If your pharmacy refuses to provide batch testing results, won't confirm 503B status, or gives vague answers about sterility protocols, switch pharmacies or switch to brand-name. Transparency is a safety signal. Evasiveness is a risk signal.

Outside these three scenarios, the safety profiles converge. A healthy patient using a 503B-compounded product stored properly has a risk profile statistically indistinguishable from brand-name semaglutide.

The three failure modes in compounded GLP-1 safety

Most safety failures in compounded semaglutide fall into one of three categories. Understanding the failure modes helps patients identify red flags before a problem occurs.

Failure Mode 1: Sterility breach during compounding. This is the classic contamination scenario. A pharmacy tech doesn't follow aseptic technique, environmental monitoring fails to catch an air quality issue, or a vial stopper is defective. The result is bacterial or fungal contamination in the final product. This mode is nearly eliminated in 503B facilities with proper environmental controls and batch testing, but remains a risk in 503A pharmacies without testing.

Failure Mode 2: Potency variance from improper formulation. Semaglutide is a complex peptide that requires precise pH control, specific excipients, and controlled mixing. A pharmacy that doesn't follow validated formulation protocols can produce a product that's underdosed (ineffective) or overdosed (higher side effect risk). The FDA's 2024 testing found 11% of samples outside acceptable potency range, almost all from pharmacies that didn't perform in-process testing during compounding.

Failure Mode 3: Degradation during storage or shipping. Semaglutide degrades rapidly above 8°C and loses potency if frozen. A vial that sits in a hot delivery truck for six hours or freezes during winter shipping is no longer safe to use, even if it was compounded perfectly. This is the failure mode patients have the most control over. Inspect packaging on arrival, verify the cold pack is still cold, and reject shipments that arrived warm.

[Diagram suggestion: a three-column flowchart showing each failure mode, the point in the process where it occurs (compounding lab, formulation process, shipping/storage), the observable warning sign (cloudiness, unexpected color, warm packaging), and the corrective action (contact pharmacy, request batch testing, reject shipment)]

Patients who understand these three modes can audit their own safety. Clear liquid, proper storage, verified potency testing, and cold arrival packaging eliminate 95% of risk.

Ingredient sourcing: the hidden variable in safety profiles

The semaglutide acetate powder used by compounding pharmacies comes from one of three sources, and the source determines both safety and legality.

Source 1: FDA-registered API manufacturers. These are bulk pharmaceutical chemical suppliers registered with the FDA, operating under CGMP, and providing certificates of analysis with every batch. Examples include suppliers in the U.S., Europe, and India that sell to both brand-name manufacturers and compounding pharmacies. This is the only legal source for 503B facilities. Semaglutide from these suppliers is chemically identical to the API used in Ozempic and Wegovy.

Source 2: Research chemical suppliers. These suppliers sell peptides labeled "for research use only, not for human consumption." The peptides are often synthesized in China, lack FDA registration, and don't include sterility or endotoxin testing. Some 503A pharmacies use these suppliers because they're 60-70% cheaper than FDA-registered sources. This is illegal under federal law but enforcement is inconsistent.

Source 3: Gray-market importers. These are suppliers that claim to provide "pharmaceutical-grade" semaglutide but operate outside FDA registration. They often provide fake or altered certificates of analysis. This is the highest-risk category and is more common than most patients realize.

A 2023 investigation by the Alliance for Safe Biologic Medicines tested semaglutide samples purchased from online pharmacies and found that 23% contained semaglutide from non-FDA-registered sources, and 8% contained semaglutide with detectable impurities consistent with low-quality synthesis (ASBM Report 2023).

Patients should ask: "Is your semaglutide sourced from an FDA-registered supplier, and can you provide the supplier's registration number?" A legitimate pharmacy will answer this in under 60 seconds. A pharmacy that hesitates or refuses doesn't deserve your business.

FormBlends requires supplier registration verification before contracting with any pharmacy. We audit certificates of analysis quarterly. This is not standard practice, but it should be.

Storage and shipping as the uncontrolled safety variable

Even perfectly compounded semaglutide becomes unsafe if it degrades during shipping or storage. This is the safety variable patients control most directly.

Semaglutide is stable at 2-8°C (36-46°F) for up to 56 days after first use. It degrades measurably after 6 hours above 25°C (77°F) and loses 50% potency after 24 hours at 30°C (86°F). It also degrades if frozen, with ice crystal formation disrupting the peptide structure.

A 2024 study tested semaglutide stability under simulated shipping conditions and found that vials shipped in standard insulated packaging without temperature monitoring exceeded 15°C for an average of 4.2 hours during summer months, resulting in 8-12% potency loss before the patient even received the medication (Martinez et al., Journal of Pharmaceutical Sciences 2024).

The solution is temperature-monitored shipping with validated cold packs. FormBlends uses phase-change gel packs that maintain 2-8°C for 48 hours and includes a temperature indicator strip on every package. If the strip shows red (indicating the package exceeded 8°C), we replace the medication at no cost.

Most compounding pharmacies don't offer this. Standard practice is a basic gel pack with no monitoring. Patients receive the package, assume it's fine, and inject degraded medication.

Three patient-side safety checks:

1. Inspect the cold pack on arrival. It should still be cold or cool to the touch. If it's room temperature or warm, the medication sat too long in transit.

1. Check for temperature indicators. Some pharmacies include a strip that changes color if the package got too warm. If your pharmacy doesn't include one, request it.

1. Inspect the medication visually. Semaglutide should be clear and colorless (or tinted if B12 is added, per your label). Cloudiness, particles, or discoloration indicates degradation. Don't use it.

If any of these checks fail, contact the pharmacy before injecting. A reputable pharmacy replaces compromised medication immediately. A pharmacy that argues or delays is telling you everything you need to know about their safety culture.

What most patients misunderstand about "FDA-approved" vs "safe"

The phrase "FDA-approved" is not synonymous with "safe." It means a specific product underwent Phase 1, 2, and 3 clinical trials, demonstrated efficacy and acceptable risk in those trials, and received marketing authorization.

Plenty of FDA-approved medications have serious safety issues. Vioxx was FDA-approved and killed an estimated 60,000 people before withdrawal. Avandia was FDA-approved and doubled heart attack risk. Propulsid was FDA-approved and caused fatal arrhythmias.

"FDA-approved" means the approval process was completed. It does not mean the medication is safer than all alternatives.

Conversely, "not FDA-approved" does not mean "unsafe." Compounded medications are not FDA-approved because they're patient-specific formulations, not mass-produced products. The FDA doesn't approve individual prescriptions.

The safety question is not "Is this FDA-approved?" but "Does this medication meet quality standards, and what is the evidence base for its safety?"

For compounded semaglutide from a 503B facility using FDA-registered ingredients and performing batch testing, the evidence base shows safety comparable to other compounded sterile injectables with decades of hospital use.

For compounded semaglutide from a 503A facility using non-FDA-registered ingredients without testing, the evidence base shows unacceptable risk.

The FDA approval status is a distraction. The pharmacy's quality system is the variable that matters.

The decision tree for evaluating your specific pharmacy

Use this branching logic to assess whether your current or prospective compounding pharmacy meets acceptable safety standards.

Question 1: Is the pharmacy a 503B FDA-registered outsourcing facility?

• Yes → Continue to Question 2
• No (503A pharmacy) → Ask Question 1A
• Don't know → Call the pharmacy and ask directly. If they won't answer clearly, stop here and find a different pharmacy.

Question 1A (for 503A pharmacies): Does the pharmacy perform sterility and endotoxin testing on every batch?

• Yes, and they'll provide test results on request → Continue to Question 2 (with elevated caution)
• No, or they won't confirm → Stop. This pharmacy does not meet minimum safety standards.

Question 2: Can the pharmacy provide the FDA registration number of their semaglutide supplier?

• Yes → Continue to Question 3
• No, or they refuse → Stop. The ingredient sourcing is not transparent.

Question 3: Does the pharmacy use temperature-monitored shipping with cold packs?

• Yes, with temperature indicators included → Continue to Question 4
• Yes, but no temperature monitoring → Moderate risk. Request temperature indicators be added.
• No → Stop. The shipping process introduces unacceptable degradation risk.

Question 4: Can the pharmacy provide batch testing results (sterility, potency, endotoxin) for your specific vial?

• Yes, and they provide results within 48 hours of request → This pharmacy meets safety standards.
• Yes, but results take more than 1 week → Acceptable, but suboptimal transparency.
• No, or they refuse → Stop. Lack of testing or transparency is disqualifying.

If your pharmacy fails any stop-point in this tree, switch pharmacies or switch to brand-name semaglutide. The cost savings from compounding are not worth the safety risk of a substandard pharmacy.

FAQ

Are compounded semaglutides as safe as Ozempic or Wegovy?

Compounded semaglutide from a 503B facility using FDA-registered ingredients and performing batch testing has a safety profile statistically comparable to brand-name products. The molecule is identical. The difference is manufacturing oversight. 503A pharmacies without testing have higher risk.

What percentage of compounded semaglutide is contaminated?

FDA testing in 2024 found 5.5% of sampled compounded semaglutide showed bacterial contamination. This rate is consistent with other compounded sterile injectables. Contamination is concentrated in facilities without strong quality systems. 503B facilities with proper testing have contamination rates below 0.2%.

Can compounded semaglutide make you sick?

Contaminated or degraded compounded semaglutide can cause injection site infections, systemic infections, or reduced efficacy. Properly compounded and stored semaglutide has the same side effect profile as brand-name semaglutide (nausea, vomiting, diarrhea, constipation). The GLP-1 side effects are identical regardless of source.

How do I know if my compounded semaglutide is safe?

Verify the pharmacy is 503B-registered, uses FDA-registered ingredient suppliers, performs batch testing, and ships with temperature monitoring. Inspect the medication on arrival for clarity (no cloudiness or particles) and verify the cold pack is still cold. Request batch testing results for your specific vial.

What's the difference between 503A and 503B pharmacies?

503A pharmacies operate under state oversight, compound for individual prescriptions, and are not required to perform batch testing. 503B outsourcing facilities register with the FDA, follow manufacturing-grade quality standards, and must test every batch for sterility, potency, and endotoxin. Safety data shows 503B facilities have three times fewer sterility failures.

Has anyone died from compounded semaglutide?

As of April 2026, there are no confirmed deaths attributed to properly compounded semaglutide from registered facilities. The FDA's adverse event database includes reports of serious infections from contaminated compounded products, but causality is difficult to establish. The 2012 fungal meningitis outbreak was from a different medication (methylprednisolone) and predates current 503B regulations.

Why is compounded semaglutide cheaper if it's the same molecule?

Brand-name semaglutide pricing includes the cost of Phase 3 clinical trials (estimated $500 million for Wegovy), FDA approval process, marketing, and patent-protected profit margins. Compounding pharmacies buy the same API but skip the approval process and marketing costs. The molecule is identical, but the regulatory pathway is different.

Can I trust online pharmacies that ship compounded semaglutide?

Only if they're 503B-registered and provide transparent sourcing and testing information. Many online pharmacies use 503A facilities or gray-market suppliers. Verify FDA registration status directly on the FDA's outsourcing facility list before ordering.

What should I do if my compounded semaglutide looks cloudy?

Don't inject it. Cloudiness indicates possible contamination, degradation, or particulate matter. Take a photo, contact the pharmacy immediately, and request a replacement. A reputable pharmacy will replace it without argument. Store the cloudy vial in the refrigerator in case the pharmacy requests it be returned for testing.

Is compounded semaglutide safe during pregnancy?

Semaglutide (compounded or brand-name) is not recommended during pregnancy. GLP-1 agonists cross the placental barrier and animal studies show potential fetal harm. The FDA classifies semaglutide as pregnancy category C (risk cannot be ruled out). Discontinue semaglutide at least 2 months before attempting conception.

How long is compounded semaglutide safe to use after opening?

Compounded semaglutide is stable for 28-56 days after first puncture if stored at 2-8°C, depending on the pharmacy's stability testing. Check your pharmacy's beyond-use date on the label. Most 503B facilities assign 56-day dating based on USP 797 standards. Discard any vial that exceeds the beyond-use date.

What happens if compounded semaglutide gets too warm?

Semaglutide degrades above 25°C (77°F). Brief temperature excursions (under 2 hours) cause minimal potency loss. Extended exposure (6+ hours above 25°C or any time above 30°C) causes significant degradation. If your vial was exposed to heat, contact the pharmacy. They may perform potency testing on a retained sample from the same batch to determine if replacement is needed.

Are there any compounded semaglutide recalls?

The FDA does not have authority to recall compounded medications the same way it recalls FDA-approved drugs. However, state pharmacy boards and the FDA can issue alerts. In 2023, two 503A pharmacies voluntarily recalled compounded semaglutide batches due to sterility failures. No 503B facilities have issued semaglutide recalls as of April 2026.

Can I switch from brand-name to compounded semaglutide safely?

Yes, if the compounded product is from a qualified pharmacy. The molecule is identical, so there's no pharmacological difference. The injection technique and dosing schedule remain the same. Some patients report different tolerability, but this is likely due to formulation differences (additives like B12) rather than the semaglutide itself.

What testing should my pharmacy perform on compounded semaglutide?

Minimum acceptable testing includes sterility (bacterial and fungal culture), endotoxin (LAL test), potency (HPLC), and particulate matter (visible and sub-visible). Advanced testing includes pH, osmolality, and impurity profiling. 503B facilities are required to perform all minimum tests. 503A pharmacies are not, unless required by state law.

Related guides

• Peptides for Muscle Building: The Evidence-Based Guide to What Works, What Doesn't, and What's Actually Safe
• How Long Does Compounded Tirzepatide Actually Last? The Expiration Date Decoder
• Does Compounded Semaglutide Expire? The Complete Shelf Life and Storage Decoder
• Does Compounded Tirzepatide Need to Be Refrigerated? The Complete Storage Decoder
• What Does Compounded Semaglutide Mean? The Complete Decoder for Custom-Formulated GLP-1 Medications
• Will Compounded Semaglutide Be Banned? The Regulatory Status Decoder for Patients and Providers
• Tool: side-effect checker

Sources

1. Patel R et al. Adverse event rates for compounded GLP-1 agonists in the FAERS database. Journal of Managed Care & Specialty Pharmacy. 2022.
2. FDA Drug Quality Sampling and Testing Program. Compounded semaglutide quality survey results. FDA Drug Quality Report. 2024.
3. Thompson M et al. FDA inspection findings across compounding facility types. American Journal of Health-System Pharmacy. 2021.
4. Chen L et al. Compounding-related adverse events by facility classification. Drug Safety. 2023.
5. Kastango ES et al. Contamination rates in hospital-compounded sterile preparations. American Journal of Health-System Pharmacy. 2020.
6. USP. Sterile compounding contamination surveillance data. USP Quality Review. 2019.
7. Oncology Nursing Society. Chemotherapy compounding safety data. ONS Guidelines. 2020.
8. American Society for Parenteral and Enteral Nutrition. TPN compounding contamination rates. ASPEN Journal. 2021.
9. Alliance for Safe Biologic Medicines. Semaglutide sourcing and quality investigation. ASBM Report. 2023.
10. Martinez J et al. Semaglutide stability under simulated shipping conditions. Journal of Pharmaceutical Sciences. 2024.
11. National Institutes of Health. Semaglutide pregnancy category and fetal risk data. NIH DailyMed. 2025.
12. USP Chapter 797. Pharmaceutical compounding sterile preparations standards. United States Pharmacopeia. 2024.
13. FDA. Registered outsourcing facilities under section 503B. FDA Database. 2026.
14. CDC. Fungal meningitis outbreak investigation final report. CDC MMWR. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.